2023 LCRF Leading Edge Research Grant Program
Benjamin Morris, PhD
University of Texas M.D. Anderson Cancer Center
Research Project:
Deep whole genome sequencing of circulating tumor DNA for studying evolution and therapy resistance in small cell lung cancer
Summary:
While most small cell lung cancers (SCLCs) initially respond to a combination of chemotherapy and immunotherapy, resistance often develops quickly. It is currently unknown how these cancers evolve to escape standard of care treatment. In this project, we will use cancer DNA collected from small blood draws to study how SCLC evolves following treatment. Our work will identify changes in cancer DNA and gene expression that drive resistance. We will also determine if resistant tumors are composed of one population of resistant cells or if multiple, hard to treat populations emerge after treatment to drive resistance. By identifying how SCLC cells change following initial treatment, our work will help identify new ways to better treat resistant SCLC in the clinic.
1-year update: spring 2025
What he’s doing:
Dr. Morris is leading critical research to better understand how small cell lung cancer (SCLC) responds to treatment by analyzing patient tumor samples before, during, and after therapy—particularly when the cancer progresses. His team is also comparing the genetic makeup of tumors in patients who respond well to treatment versus those whose cancer proves resistant.
What it could mean for patients:
By uncovering the genetic changes that occur throughout treatment, Dr. Morris hopes to identify patterns that could guide the development of more effective therapies for SCLC. Since this type of lung cancer has historically been difficult to treat, understanding its biology is essential to finding new and improved treatment strategies.